4D Molecular Therapeutics (FDMT) Return on Capital Employed Growth (1y) (2022 - 2026)
4D Molecular Therapeutics (FDMT) Return on Capital Employed Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 45.00 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1,490.00 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1,629.00 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.41 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -310.00 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3,193.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 399.00 |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 458.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 458.00 |
| Mar 31, 2026 | 361.00 |
| Dec 31, 2025 | -138.00 |
| Sep 30, 2025 | -2,706.00 |
| Jun 30, 2025 | -2,623.00 |
| Mar 31, 2025 | -1,397.00 |
| Dec 31, 2024 | 5.00 |
| Sep 30, 2024 | 206.00 |
| Jun 30, 2024 | 1,962.00 |
| Mar 31, 2024 | 2,126.00 |
| Dec 31, 2023 | 909.00 |
| Sep 30, 2023 | 719.00 |
| Jun 30, 2023 | -716.00 |
| Mar 31, 2023 | -2,218.00 |
| Dec 31, 2022 | -1,769.00 |
| Sep 30, 2022 | -982.00 |
| Jun 30, 2022 | -1,349.00 |
| Mar 31, 2022 | -239.00 |